scPharmaceuticals (US:SCPH)2024-05-14 23:02Financial Data and Key Metrics Changes - The company reported a net loss of $14.1 million for Q1 2024, compared to a net loss of $11.2 million for Q1 2023 [19] - Product revenues were $6.1 million for Q1 2024, up from $2.1 million in Q1 2023, reflecting a significant increase in demand for FUROSCIX [19] - The gross to net discount during Q1 was 19%, slightly up from 2023, with expectations to reach 30% to 35% by the end of the year [69] Business Line Data and Key Metrics Changes - The average number of doses per prescription filled was 6.1 in Q1 2024, up from 5.9 in Q4 2023 [5] - A total of 17,736 doses were written in Q1 2024, with 8,074 doses filled, impacted by the Change Healthcare cyber-attack [71] - The sales force conducted 2,938 in-services from launch through March 31, 2024, an increase from 2,331 in-services completed as of December 31, 2023 [5] Market Data and Key Metrics Changes - The company is seeing a growing number of providers comfortable prescribing FUROSCIX to heart failure patients during critical intervention windows [2] - Approximately 70% of co-pays for FUROSCIX are $100 or less, moving closer to the goal of 75% or more over time [79] - The company anticipates that cancellation rates will normalize over time, with a current cancellation rate of 19% in Q1 2024 [66] Company Strategy and Development Direction - The company is focused on expanding the indication of FUROSCIX to include Class 4 heart failure patients, with a PDUFA date set for August 2024 [65] - A pivotal PK study for a new low-volume auto injector is underway, which could reduce manufacturing costs and improve treatment flexibility [4] - The company is engaged in a multi-channel marketing campaign to drive brand awareness and adoption of FUROSCIX [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued comfort of treating physicians in prescribing FUROSCIX, despite challenges from the Change Healthcare cyber-attack [58] - The company expects momentum to continue as more physicians gain confidence in prescribing FUROSCIX and as they make progress with payor formularies [58] - Management noted that the transition to a new patient services provider is expected to improve patient and physician experiences [64] Other Important Information - Research and development expenses increased to $2.7 million in Q1 2024 from $2.1 million in Q1 2023, primarily due to device development and clinical study costs [72] - Selling, general, and administrative expenses rose to $17.4 million in Q1 2024 from $10.9 million in Q1 2023, driven by increased employee-related and commercial costs [72] Q&A Session Summary Question: Revenue flat despite increased doses filled - Management explained that the revenue of $6.1 million was flat due to a large order from Kaiser Direct in Q4 that did not count in billed doses but affected net revenue [22] Question: Feedback from doctors on prescribing - Management indicated that there is no significant pushback from doctors, and demand is increasing month over month [74] Question: Plans for Class 4 heart failure education - Management stated that they will educate physicians about the Class 4 indication as soon as approval is received, using both direct and non-direct promotion [27] Question: Impact of Change Healthcare on prescriptions - Management noted that while there was a slight lull in prescriptions during the cyber-attack, overall trends remained positive, with scripts growing towards the end of the quarter [37] Question: Future dosing expectations for Class 4 and CKD - Management anticipates that dosing for Class 4 patients may remain around 6 doses, while CKD patients may have similar dosing to heart failure patients, around 4 to 5 doses [42]